Pirlindole mesylate

Pirlindole mesylate selectively inhibits MAO-A in rat brain with an IC₅₀ value of 250 nM, and its inhibitory potency against MAO-B in rat brain and heart is more than 200-fold lower^[3].
Pirlindole (0.1 nM-34 μM) mesylate slightly increases electrically stimulated dopamine release at concentrations of 0.1-10 nM, and doubles electrically induced norepinephrine and serotonin release at concentrations of 4.5 μM and 34 μM, respectively, in rat cortical slices^[3].
Pirlindole (3 μg/mL) mesylate prolongs the refractory period of electrically stimulated rabbit atrial contractions^[3].
Pirlindole (Up to 0.5 mg per plate) mesylate shows no mutagenic activity in the Ames test using Salmonella typhimurium strains TA 98, TA 1537, TA 100, and TA 1535, with or without metabolic activation^[3].
Pirlindole (10 μM) mesylate potently inhibits CV-B3 replication in HeLa R19 cells, as evidenced by a significant reduction in GFP fluorescence intensity and extremely low cytotoxicity^[4].
Pirlindole (0.3-30 μM; 8 h postinfection) mesylate inhibits the replication of CV-B3 in BGM cells and EV-D68 in HeLa R19 cells, exhibits moderate activity against EV-A71, and shows no activity against EV-C, rhinoviruses or EMCV^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.